MLAB
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Mesa Laboratories, Inc. is a provider of life sciences tools and critical quality control solutions for regulated applications in the pharmaceutical, healthcare, and medical device industries. The company operates through four segments: Sterilization and Disinfection Control, Biopharmaceutical Development, Calibration Solutions, and Clinical Genomics. Its product portfolio includes biological, chemical, and cleaning indicators, data loggers, continuous monitoring systems, gas and air flow measurement devices, and renal care quality control instruments. In the Clinical Genomics segment, the company offers the MassARRAY system for high-throughput genetic analysis, serving clinical research labs and contract research organizations. Mesa Laboratories manufactures products in the United States and Europe, with sales operations in North America, Europe, and the Asia Pacific region. The company was organized in 1982 and serves customers including hospitals, dental offices, pharmaceutical manufacturers, and medical device makers.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Medical Instruments & Supplies Homepage mesalabs.com
Sector Healthcare IR page investors.mesalabs.com/home/default.aspx
Tags
sterilization indicators, biological indicators, chemical indicators, cleaning indicators, genetic analysis, mass spectrometry, pcr, process monitoring, gas flow measurement, renal care, dialysate meters, quality control, GKE Clean-Record, Apex, EZTest, MassARRAY, Agena Bioscience, Gyros Protein Technologies
Press page —

Metrics

Valuation  
Market cap $ 729.478M
Market cap (USD) $ 729.478M
P/E 112.99
PEG 1.21
P/BV 3.75
P/S 2.90
P/OCF 14.15
P/FCF 14.75
Dividend yield <0.01%
Turnover / mcap —
Returns  
ROE 3.9%
ROI 2.6%
ROIC 4.0%
Profit margin 2.7%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 93.3%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 33.2%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 11
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007
Revenue 249.13M 240.978M 216.187M 219.08M 184.335M 133.937M 117.687M 103.135M 96.179M 93.665M 84.659M 71.33M 52.724M 46.435M 39.616M 34.227M 21.536M 19.558M 17.242M
Net profit 6.712M -1.974M -254.246M 930K 1.871M 3.274M 1.349M 7.484M -2.962M 11.183M 11.169M 9.583M 9M 8.45M 7.919M 6.183M 4.79M 4.61M 3.958M
Free cash flow 39.581M 42.559M 41.566M 23.439M 34.791M 35.081M 25.061M — — — — — — — — — 4.399M 4.409M 2.252M

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2009 FY 2008 FY 2007
Share price 88.42 118.66 109.73 174.73 254.88 243.5 226.09 230.5 148.44 122.7 96.35 72.2 90.25 53.09 49.34 29 17.42 23.63 19.24
Price performance 12m -0.25 0.08 -0.37 -0.31 0.05 0.08 -0.02 0.55 0.21 0.27 0.33 -0.2 0.7 0.08 0.7 0.26 -0.26 0.23 —

Filed figures

Figure Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Balance sheet detail
Trade receivables (USD) 14.3M 14.3M 12.5M 21.1M 23.8M 41.2M 42.6M 39.1M 42M 44.1M
↳ YoY growth -6.5% -0.1% -12.5% +68.8% +12.6% +73.3% +3.2% -8.2% +7.5% +5.1%
↳ 5y CAGR +17.2% +11.0% +6.2% +11.7% +9.2% +23.6% +24.4% +25.6% +14.7% +13.1%
Borrowings, current (USD) 1.13M 1.63M 2.13M — — — — — — —
Borrowings, non-current (USD) 53.7M 44.6M 20.6M — — — — — — —
Lease liabilities (USD) — — — 1.1M 1.02M 2.77M 2.87M 9.6M 15.9M 17.3M
Cash and deposits (USD) 5.82M 5.47M 10.2M 81.4M 264M 49.3M 32.9M 28.2M 27.3M 26.9M
Intangible assets (USD) 37.8M 42.9M 33.2M 120M 112M 250M 217M 114M 96.9M 83.3M
Right-of-use assets (USD) — — — — — — 8.69M 9.67M 16.4M 17.5M
Net debt (borrowings + leases - cash) (USD) 49M 40.8M 12.6M — — — — — — —
Cash flow detail
Operating cash flow (USD) 7.75M 24.8M 30.6M 26.6M 37.1M 39.2M 28M 44.1M 46.8M 42.8M
Purchases of property, plant and equipment (USD) — -2.8M -1.26M -1.5M -1.99M -4.43M -4.54M -2.57M -4.25M -3.25M
Purchases of intangible assets (USD) — — — — — — 0.00 0.00 -250,000 0.00
Change in receivables (cash effect) (USD) 994,000 680,000 1.59M -1.67M -647,000 -6.75M -2.12M 4.94M -2.93M -3.21M
Change in inventories (cash effect) (USD) 295,000 2.29M 2.57M 414,000 929,000 -1.05M -10.2M 2.56M 1.15M -4.43M
Change in payables (cash effect) (USD) -655,000 212,000 1.09M -61,000 967,000 1.37M -1.55M -97,000 -388,000 -1.2M
Dividends paid (cash effect) (USD) -2.36M -2.41M -2.46M -2.72M -3.17M -3.34M -3.41M -3.45M -3.47M -3.52M
Interest paid (cash effect) (USD) -1.38M -1.96M -1.64M -1.63M -2.37M -2.76M -3.49M -4.65M -11.1M -10M
Income taxes paid (cash effect) (USD) -5.61M -4.55M -5.87M -2.63M -1.37M -3.05M -1.36M -4.59M -5.73M -1.87M
Share-based compensation (USD) 1.41M 1.67M 4.21M 5.53M 9.27M 11.4M 12.5M 11.9M 13.1M 17.9M
Operating cash flow before change in receivables (USD) 6.76M 24.1M 29M 28.2M 37.7M 46M 30.1M 39.2M 49.7M 46M
Free cash flow (OCF - PPE - intangibles) (USD) — 22.9M 29.3M 25.1M 35.1M 34.8M 23.4M 41.6M 42.3M 39.6M
Income detail
Research and development expense (USD) 4.16M 3.54M 3.51M 6.36M 10.4M 15.8M 20.5M 19.3M 19.5M 20.3M
↳ 5y CAGR +25.1% +12.0% +8.6% +14.0% +21.2% +30.6% +42.1% +40.7% +25.2% +14.3%
Total comprehensive income (USD) 10.6M -638,000 5.11M -6.59M 29.8M -10.6M -15.5M -256M 3.01M 13.1M
Comprehensive income to owners (USD) 10.6M -638,000 5.11M -6.59M 29.8M -10.6M -15.5M -256M 3.01M 13.1M
Provision for credit losses (USD) 68,000 17,000 13,000 1,000 100,000 304,000 736,000 790,000 218,000 1.5M
Credit cost ratio (credit losses / average receivables) (%) 0.5% 0.1% 0.1% 0.0% 0.4% 0.9% 1.8% 1.9% 0.5% 3.5%
Reported Jun 3, 2019 Jun 1, 2020 Jun 1, 2020 Nov 5, 2020 Feb 3, 2022 May 31, 2022 May 28, 2025 May 28, 2025 May 28, 2025 Jun 3, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Lakewood, Colorado, November 9, 2026 – Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced results for its second fiscal quarter (“2Q27”) ended September 30, 2026, and issued full-year guidance for the first time (dollars in thousands, except per-share amounts).

2Q27 Financial Summary – (comparisons are versus the same prior year period)

• Revenues increased 2.6% to $62,336

• Non-GAAP organic and constant currency organic revenues1 growth was 2.6% and 3.1%, respectively

• Non-GAAP revenues excluding Clinical Genomics6 increased 5.2% (5.8% constant currency) to $52,171; for the first six months, 3.2% (3.3% constant currency) to $102,020

• Sterilization and Disinfection Control revenues increased 14.6% to $25,342; over the last twelve months, the division increased 8.5% to $103,897, the highest twelve-month total revenues in the division’s history

• Operating income increased 77.6% to $8,388

• Net income increased 75.3% to $4,341

• Non-GAAP Adjusted EBITDA2 increased 21.1% to $17,317, or 27.8% of revenues

• Repaid $11,406 of debt, and redu

October 28, 2026

Lakewood, Colo., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced it will release financial results for its second fiscal quarter (“2Q27”) ended September 30, 2026 following market close on Monday, November 9, 2026. The Company will also hold its earnings conference call the same day at 4:30 p.m. Eastern Time to discuss its financial results in further detail. The call will conclude with a Q&A session with analysts.

Details for the conference call can be found below:

Date: Monday, November 9, 2026
Time: 4:30 p.m. Eastern Time
Toll Free: 1-833-461-5787
International: 1-585-542-9983
Conference ID: 725 558 996
Webcast: https://events.q4inc.com/attendee/725558996

Please call the conference telephone number or log on to the web access link five minutes prior to the start time.

A replay of the call will remain available for 45 days via the investors section of the Mesa Labs website at https://investors.mesalabs.com/ .

About Mesa Laboratories, Inc.

Mesa is a global leader in the design and manufacture of critical quality control solutions and life sciences tools for regulated applications in the pharmaceutical, healthcare and medical device industries.  With manufacturing operations in the United States and Europe, and commercial reach across North America, Europe, the Asia Pacific Region, and throughout the world, we serve customers whose applications demand accuracy, reliability and regulatory compliance.

October 13, 2026

The Restructuring Program focuses Clinical Genomics on profitability and adds resources in Sterilization and Disinfection Control, Calibration Solutions and Asia

LAKEWOOD, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ: MLAB) (“Mesa,” “we,” “us” or “our”), a global leader in the design and manufacture of critical quality control solutions and life sciences tools, today announced a savings plan (the “Savings Plan”) expected to reduce annualized operating costs by approximately $9.3 million. The Savings Plan consists of a global restructuring program (the "Restructuring Program"), a reduction in our San Diego, California facility footprint and reduced third-party spending. We plan to reinvest approximately $4.3 million of the savings into the business to drive profitable growth, for a net annualized cost reduction of approximately $5.0 million.

The Restructuring Program is designed to allocate resources toward opportunities that we expect to expand future profitability and create long-term value for our shareholders. As part of the Restructuring Program, we will eliminate approximately 40 positions, or approximately 6% of Mesa’s total employee base, with limited impact on manufacturing operations.

The cost reductions are concentrated primarily in our Clinical Genomics division, with additional reductions in corporate functions. We will reinvest a portion of the savings in selected growth and infrastructure priorities, including adding business development capacity in Calibration Solutions, commercial resources primarily in Asia, and key corporate positions. We expect these investments to support more profitable growth.

“Mesa is a set of durable, regulation-embedded franchises with real and growing earnings power, and fixable execution problems we have already begun to fix,” said Dr. Siddhartha Kadia, President and Chief Executive Officer. “My focus is disciplined execution and consistent, profitable growth across our four divisions.

“As I said on our first quarter call, we are managing Clinical Genomics deliberately, with full attention to its cost structure and returns. Following the business reviews I have completed over my first six months, we are managing it for profitability, not for scale. These were difficult decisions, and we approached each one with care and respect for our team members. At the same time, we have a responsibility to position the business for sustainable, profitable growth.

“This is not a broad cost reduction. It follows a decision about which customers Clinical Genomics is built to serve. We are focusing Clinical Genomics on pharmacogenomics and oncology, on customer accounts that use the instrument at scale, and we are sizing the organization for that. This is not a decision to pull back from specific regions; if an account uses the instrument at scale, we want to serve it wherever it is. Revenue will be lower as a result, but we expect profitability to be meaningfully higher as the cost comes out, and gross profit percentage to improve, because the revenue we are stepping away from is the lowest-margin revenue we have in Clinical Genomics. We are also redirecting resources to accelerate standard product launches, the fastest-growing part of the Clinical Genomics portfolio. Our obligation is to make every business in this portfolio earn its cost of capital, and we will report against that standard.”

ADDING RESOURCES IN ASIA

We are adding commercial and technical resources in Asia for Sterilization and Disinfection Control and Biopharmaceutical Development, including a leader for Asia outside of China. These investments better align our resources with the businesses that generate most of our revenue in the region but have historically received a relatively small share of our resources there, and we expect them to drive profitable growth in the region over time.

FINANCIAL IMPACT

The Restructuring Program consists primarily of workforce reductions and, to a lesser extent, consolidation of the Clinical Genomics facility footprint, including exiting our Hamburg, Germany facility when its lease expires in February 2027. Actions began after Board approval, and we expect them to be substantially complete by the end of fiscal year 2027, except for certain international employee exits with protected notice periods, which we expect to complete in the first half of fiscal year 2028.

We estimate that the Restructuring Program will result in total pre-tax charges of approximately $2.6 million to $3.4 million, primarily during the second half of fiscal year 2027. These charges are expected to consist primarily of employee-related costs of approximately $2.3 million to $3.0 million, net of an expected non-cash reversal of approximately $0.3 million of previously recognized stock-based compensation expense, and other exit costs, including third-party costs to administer these exits, of approximately $0.3 million to $0.4 million. We expect related cash expenditures of approximately $2.9 million to $3.7 million, substantially all of which will occur over the next 12 months.

We expect the Savings Plan to be fully reflected in our annualized cost structure by the end of fiscal year 2028, at a net annualized cost reduction of approximately $5.0 million after the reinvestment described above. These figures reflect cost reductions only; they exclude the expected decrease in Clinical Genomics revenue and increase in its gross profit percentage described above.

We will report second quarter fiscal year 2027 results on November 9, 2026, when we will also provide company-level fiscal year 2027 guidance that reflects the Savings Plan and the expected decrease in Clinical Genomics revenue.

ABOUT MESA LABORATORIES

Mesa is a global leader in the design and manufacture of critical quality control solutions and life sciences tools for regulated applications in the pharmaceutical, healthcare and medical device industries. With manufacturing operations in the United States and Europe, and commercial reach across North America, Europe, the Asia Pacific Region, and throughout the world, we serve customers whose applications demand accuracy, reliability and regulatory compliance.

FORWARD-LOOKING STATEMENTS

Certain statements in this press release, such as statements relating to our estimates of annualized cost reductions, reinvestment, net annualized cost reduction, positions to be eliminated, pre-tax charges and related cash expenditures as a result of the Restructuring Program; the expected effects of the Savings Plan and the Restructuring Program on Clinical Genomics revenue and profitability, and the timeline for completion; and our expected reporting date and plans to provide fiscal year 2027 guidance, may be considered forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include those preceded by, followed by or that include the words "will," "may," "could," "would," "should," "believe," "expect," "anticipate," "plan," "estimate," "target," "project," "intend" or similar expressions. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the timing and outcome of required employee consultation and notice processes in certain jurisdictions, the disruption of ongoing business, customer reactions to our narrower commercial focus in Clinical Genomics, our ability to recruit for new positions, our ability to achieve the expected benefits of the Restructuring Program, and other factors which can be found in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended March 31, 2026. Any forward-looking statement speaks only as of the date on which it is made. We do not undertake or assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Prompts

Mesa Laboratories, Inc. (ticker MLAB), listed in United States.

ETFs Holding Mesa Laboratories, Inc.

ETF Weight in ETF Shares Market value As of
KDVD 1.68% 1,425 $ 141.859K Jun 30, 2026
JSML 0.84% 30,109 $ 3.035M Jul 31, 2026
RUSC 0.27% 2,160 $ 215.028K Jun 30, 2026
FSEG 0.14% 80 $ 7,964.00 Jun 30, 2026
FESM 0.13% 74,048 $ 7.371M Jun 30, 2026
FEAC 0.05% 132 $ 13.141K Jun 30, 2026
AVSC 0.05% 12,927 $ 1.733M Nov 16, 2026
PSC 0.05% 11,527 $ 1.148M Jun 30, 2026
IVSS 0.04% 117 $ 11.647K Jun 30, 2026
RESM 0.02% 9 $ 895.95 Jun 30, 2026
DFAT 0.02% 42,488 $ 5.744M Nov 12, 2026
DFAS 0.01% 36,430 $ 4.925M Nov 12, 2026
DXUV 0.01% 2,965 $ 400.868K Nov 12, 2026
DFAC 0.00% 20,863 $ 2.821M Nov 12, 2026
DFSU 0.00% 365 $ 49.348K Nov 12, 2026
DCOR 0.00% 5,691 $ 769.423K Nov 12, 2026
DFAU 0.00% 1,599 $ 216.185K Nov 12, 2026
DFUS 0.00% 1,639 $ 221.593K Nov 12, 2026
EBI 0.00% 8 $ 1,022.96 Aug 31, 2026